EP1002123A1 - Resolution cinetique enzymatique d'un intermediaire utilise pour la preparation de composes tricycliques substitues - Google Patents

Resolution cinetique enzymatique d'un intermediaire utilise pour la preparation de composes tricycliques substitues

Info

Publication number
EP1002123A1
EP1002123A1 EP98928889A EP98928889A EP1002123A1 EP 1002123 A1 EP1002123 A1 EP 1002123A1 EP 98928889 A EP98928889 A EP 98928889A EP 98928889 A EP98928889 A EP 98928889A EP 1002123 A1 EP1002123 A1 EP 1002123A1
Authority
EP
European Patent Office
Prior art keywords
trifluoroethyl
formula
compound
acylation
acylating agent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP98928889A
Other languages
German (de)
English (en)
Inventor
William Brian Morgan
Jinchu Liu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Sharp and Dohme Corp
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Publication of EP1002123A1 publication Critical patent/EP1002123A1/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P41/00—Processes using enzymes or microorganisms to separate optical isomers from a racemic mixture
    • C12P41/006—Processes using enzymes or microorganisms to separate optical isomers from a racemic mixture by reactions involving C-N bonds, e.g. nitriles, amides, hydantoins, carbamates, lactames, transamination reactions, or keto group formation from racemic mixtures
    • C12P41/007—Processes using enzymes or microorganisms to separate optical isomers from a racemic mixture by reactions involving C-N bonds, e.g. nitriles, amides, hydantoins, carbamates, lactames, transamination reactions, or keto group formation from racemic mixtures by reactions involving acyl derivatives of racemic amines
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P17/00—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms
    • C12P17/16—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms containing two or more hetero rings
    • C12P17/165—Heterorings having nitrogen atoms as the only ring heteroatoms

Definitions

  • This invention provides an enzymatic process for preparing optically enriched intermediates useful in the preparation of substituted tricyclic compounds known as antihistamines and as inhibitors of famesyl protein transf erase (FPT).
  • the process of this invention is useful in preparing intermediates useful in the preparation of FPT inhibitors disclosed, for example, in International Publication Number W095/10516, published April 20, 1995.
  • the resolutions suffer from low reactivity and/or selectivity.
  • This invention provides a highly selective process for preparing a substituted (6,11 -dihydro-5H-benzo[5,6]cyclohepta[1 ,2-b]-pyridin-11 - yl)piperidine compound of the formula (+)-I
  • R, R 1 , R 2 , R 3 and R 4 are independently selected from the group consisting of hydrogen, halo, C-i-C ⁇ alkyl, amino, -OCH3, -OCF3 and CF3, and the dotted line represents an optional double bond; comprising:
  • the enzyme is a hydrolase and wherein the acylating agent is of the formula R 5 COOR 6 , wherein R 5 is C1-C-15 alkyl, halo methyl, aryl, benzyl or benzyloxy, R 6 is alkyl, C1-C6 alkenyl, -COR 7 , trifluoroethyl, -CH 2 CH(OCOR 7 )CH2 ⁇ COR 7 , halo methyl or benzyl, and R 7 is C ⁇ -C ⁇ 5 alkyl; and
  • step (c) optionally converting an undesired isomer from step (a) wherein a double bond is present to the racemate by heating, and resubjecting the racemate to enzymatic acylation and hydrolysis; or
  • Preferred compounds of formula (+)-I made by this process are those wherein R 3 is not hydrogen. Also preferred are compounds wherein R is halo. Still another group of preferred compounds is that wherein R 1 is hydrogen and R, R 2 , and R 3 are selected form the group consisting of halo. Halo is preferably Cl or Br.
  • halo means fluoro, chloro, bromo and iodo, with chloro and bromo being preferred.
  • aryl means phenyl, naphthyl, substituted phenyl or substituted naphthyl, wherein “substituted” means 1-3 substituents indpendently selected form the group consisting of C-I-C6 alkyl, C-i-C ⁇ alkoxy, halo, NO2 and halo methyl.
  • acylating enzymes may have opposing selectivity, and therefore may involve either direct or subtractive resolution. That is, some enzymes may acylate the desired isomer, requiring separation of the isomers, followed by hydrolysis to obtain the desired product (i.e., direct resolution, as claimed in step (1)), while others may acylate the undesired isomer, requiring only separation of the isomers (no hydrolysis) to obtain the desired isomer (i.e., subtractive resolution, as claimed in step (2)).
  • Preferred enzymes are Toyobo LIP-300/301 , Altus Chiro CLECTM PC, Boehringer Mannheim Lipase, Novo SP435 and Novozym 435.
  • Acylating agents of formula R 5 COOR 6 are commercially available or can be prepared by known methods.
  • Preferred acylating agents are trifluoroethyl acetate (TFEOAc), trifluoroethyl butyrate (TFEOBu), trifluoroethyl isobutyrate (TFEOiBu), trifluoroethyl benzoate (TFEBenz), triacetin and tributyrin.
  • the enzymatic acylation may be carried out in a solvent such as an alkyl acetate such as methyl acetate (MeOAc) or isopropyl acetate, t-butyl methyl ether (TBME), tetrahydrofuran (THF), acetone, acetonitrile, t-amyl alcohol, t-butyl alcohol, pyridine or dioxane.
  • a solvent such as an alkyl acetate such as methyl acetate (MeOAc) or isopropyl acetate, t-butyl methyl ether (TBME), tetrahydrofuran (THF), acetone, acetonitrile, t-amyl alcohol, t-butyl alcohol, pyridine or dioxane.
  • a solvent such as an alkyl acetate such as methyl acetate (MeOAc) or isopropyl acetate, t-butyl
  • the reaction is carried out in a temperature range of 0 to 50°C, preferably at 25 to 30°C (e.g., ambient temperature).
  • the reaction time ranges from 18 to 48 hours, with 24 hours being preferred.
  • the enzyme is added at a ratio of about 1 : 2 times the amount of the starting material , preferably about 2 times the amount.
  • the acylating agent is present at about 2 to 10 times the starting material, preferably about 3 times the amount of starting material when the enzyme is present at 2 times the amount of the starting material.
  • the hydrolysis is carried out using standard procedures well known in the art. For example, the acylated compound is refluxed with an acid such as H2SO4. The desired isomer is then recovered by precipitating out by adding a base such as NaOH.
  • the reaction is preferably carried out under anhydrous conditions.
  • the solvent, or acylating agent when used as the solvent can be anhydrous, or the solution of the starting material in the solvent, or acylating agent when used as the solvent, can be dried by azeotropic distillation before the enzyme is added.
  • the enzyme should be dried under vacuum before adding to the solution, preferably to ⁇ 700 ppm water.
  • the undesired (-) isomer can be recovered from enzymatic isobutyrylation of racemic II. Heating (-)-ll in diphenyl ether or diethylene glycol dibutyl ether (5-15:1 , v:v) at 200-260°C, preferably 210°C, for 0.5- 26 hours results in complete racemization to racemic II which can be recovered in 77-95% yield with 93-99% purity.
  • the recovered racemic II undergoes the enzymatic isobutyrylation under the same conditions as above.
  • Previous methods used to resolve isomers to obtain compounds of formula I involved the resolution of a compound of formula ( ⁇ )-IIa by chiral chromatography or chemical resolution using stiochiometric amounts of a resolving agent.
  • the process claimed herein uses a biocatalyst to effect the resolution, the biocatalyst being reusable up to 15 times.
  • compounds lib are chiral atropisomers at room temperature due to restricted rotation about the double bond.
  • the isomers can be racemized at high temperatures.
  • the undesired (-) isomer can be isolated, racemized at 200-260°C, preferably at 210°C, and then subjected to a further enzymatic acylation to increase throughput of ( ⁇ )-IIIa.
  • the products of this process are intermediates useful in the preparation of tricyclic compounds useful as famesyl protein trasnsferase inhibitors such as those disclosed in International Publication Number WO95/10516, published April 20, 1995.
  • ee s is the enantiomeric excess of the unreacted starting material
  • eep is the enantiomeric excess of the product
  • c is the conversion (ee s /(ee s + ee p ))
  • E is the Enantiomeric Ratio: (ln[(1-ee s ) (1-c)/ln[(1+ee s ) (1-c)] or ln[1-c(1+ee p )]/ln[1-c(1+ eep)]);
  • Ac is acetyl
  • OAc is acetate
  • Me is methyl
  • Et is ethyl
  • Pr is propyl
  • TFE is trifluoroethyl.
  • Runs 2,3, 5-11 ( ⁇ )-IIc, 10 mg; Trifluoroethyl Acetate, 20 equiv; TBME, 1.0 mL; RT, 250 ⁇ m.
  • Runs 1 ,4 ( ⁇ )-IIc, 10 mg; CaC ⁇ 3, 30-40 mg; MeOAc, 1.0 mL (as solvent and acylating agent); RT; 250 rpm.
  • Run12 (+)-IIc, 12 mg; Trifluoroethyl acetate, 5 equiv.; TBME, 1.0 mL; RT, 250 rpm B.
  • Runs 1-9 ( ⁇ )-IIc (50 mg, 50mM), Toyobo LIP-300 (50-55 mg), TFEOiBu (5 eq., except Runs 1-3 which used solvent as acylating agent), Solvent (2.0 mL), 4A Sieves (47-59 mg), 250 rpm, RT, 22.25 h.
  • Runs 1 ,3-7,9, 13-15 ( ⁇ )-IId, 7-11 mg; TFEOAc, 50 mL, 14-25 equiv.; SP435.8-13 mg; Solvent, 2.0 mL, RT, 250 ⁇ m.
  • Runs 2, 8, 10-12 ( ⁇ )-IId, 12-15 mg; TFEOAc, 100 mL, 25-31 equiv.(except Run 2 which used solvent as the acylating agent); SP 435, 4-7 mg; Solvent, 2.0 mL; 250 rpm.
  • Runs 1 , 4-9, 11-17, 19 ( ⁇ )-IId ,4.9 mg; TBME or neat acylating agent, 1.0 mL; SP 435, 6.2-10.8 mg; 250 rpm; RT.
  • Run 1 1 , 5 mg; LIP-301 , 10 mg; Trifluoroethyl isobutyrate, 10 equivs.; TBME, 1.0 mL; 200 rpm; RT
  • Run 2 2, 5.4 mg; LIP-301 , 16.6 mg; Trifluoroethyl isobutyrate, 20 equivs.; TBME, 1.0 mL; 200 rpm, RT.
  • Run 3 3, 0.2 g; LIP-301 , 0.4 g; Trifluoroethyl isobutyrate, 10 equivs.; TBME, 4 mL;
  • TBME (600 mL) was stirred at ambient temperature for 1 h, then filtered to remove a small amount of insoluble material. The solution was dried by azeotropic distillation; after 200 mL was distilled, a further 200 mL of TBME was added to the reaction mixture. After a total of 400 mL had been distilled, the moisture content (Karl-Fischer) of the solution was 214 ppm. Toyobo LIP-300 (40 g; 1282 ppm water) was added to the reaction mixture and stirred for 0.5 h; moisture content at this stage was 250 ppm.
  • Trifluoroethyl isobutyrate (19.1 mL, 3 equivs.) was added and the mixture was stirred at ambient temperature. The reaction was terminated after 24 h. The enzyme was removed by filtration and washed with TBME (100 mL).
  • the reaction was stirred at room temperature under N 2 for 24 h.
  • the enzyme was then removed by filtration and washed with TBME (0.9 L).
  • the combined filtrates were extracted sequentially with three portions of 0.5 M H2SO4 (450 mL, 225 mL and 225 mL). These combined acidic extracts contained the unreacted (-)-llc.
  • the organic layer was then extracted with two portions of 6M H2SO4 (135 mL and 135 mL). These combined acidic extracts contained the product isobutyramide (+)-lllb.
  • (+)-lc The combined 6M H2SO4 extracts were heated at reflux for 14 .5 h, then cooled to room temperature. The reaction mixture was then added slowly to a cold, vigorously stirred mixture of NH4OH (900 mL) and CH3CN (270 mL). The solid which precipitated was filtered, washed with water and dried (40.5 g, 43.5%; 0.960 ee).
  • Isolation of (-)-llb The combined 0.5 M H2SO4 extracts were added slowly to a cold, vigorously stirred mixture of NH4OH (450 mL) and CH3CN (270 mL).
  • the combined filtrate was extracted with three portions of 0.5 M H2SO4 (150 mL, 75 mL and 75 mL) to remove the unreacted (-)-llc.
  • the organic layer was then extracted with two portions of 6M H2SO4 (45 mL and 45 mL) which were combined and refluxed for 16 h.
  • the cooled reaction mixture was then added slowly to a vigorously stirred, cold mixture of NH4OH (300 mL) and CH3CN (90 mL).
  • the precipitated (+)-lc was filtered, washed with water and dried: (13 g, 43%; 0.986 ee).

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Analytical Chemistry (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La présente invention concerne un procédé de préparation d'un composé de pipéridine substitué (6,11-dihydro-5H-benzo[5,6]cyclohepta[1,2-b]pyridin-11-yl) représenté par la formule ((+)-I) dans laquelle R, R?1, R2, R3 et R4¿ sont indépendamment sélectionnés dans le groupe constitué de hydrogène, halo, C¿1?-C6 alkyle, amino, -OCH3, -OCF3 et CF3, et la ligne en pointillé représente une double liaison facultative. Ledit procédé consiste à catalyser, de manière enzymatique, l'acylation d'un composé représenté par la formule ((±)-II) dans laquelle les variables sont telles que définies ci-dessus, et à hydrolyser le produit à obtenir ((+)-I).
EP98928889A 1997-06-17 1998-06-15 Resolution cinetique enzymatique d'un intermediaire utilise pour la preparation de composes tricycliques substitues Withdrawn EP1002123A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US877675 1992-05-01
US87767597A 1997-06-17 1997-06-17
PCT/US1998/011501 WO1998058073A1 (fr) 1997-06-17 1998-06-15 Resolution cinetique enzymatique d'un intermediaire utilise pour la preparation de composes tricycliques substitues

Publications (1)

Publication Number Publication Date
EP1002123A1 true EP1002123A1 (fr) 2000-05-24

Family

ID=25370483

Family Applications (1)

Application Number Title Priority Date Filing Date
EP98928889A Withdrawn EP1002123A1 (fr) 1997-06-17 1998-06-15 Resolution cinetique enzymatique d'un intermediaire utilise pour la preparation de composes tricycliques substitues

Country Status (9)

Country Link
EP (1) EP1002123A1 (fr)
JP (1) JP3421355B2 (fr)
AR (1) AR015892A1 (fr)
AU (1) AU8058398A (fr)
CA (1) CA2293708C (fr)
IN (1) IN187248B (fr)
MY (1) MY133532A (fr)
WO (1) WO1998058073A1 (fr)
ZA (1) ZA985217B (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6706883B1 (en) 1998-07-02 2004-03-16 Schering Corporation Process for producing (8-chloro-3,10-dibromo-6,11-dihydro-5H-benzo[5,6]cyclohepta[1,2-B]pyridin-11-YL)-1-piperdine
JP2002519419A (ja) * 1998-07-02 2002-07-02 シェーリング コーポレイション （８−クロロ−３，１０−ジブロモ−６，１１−ジヒドロ−５ｈ−ベンゾ［５，６］シクロヘプタ［１，２−ｂ］ピリジン−１１−イル）−１−ピペリジンを生成するためのプロセス
ATE346159T1 (de) * 2000-05-08 2006-12-15 Pfizer Prod Inc Enzymatische spaltung von selektiven modulatoren des östrogenrezeptors

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO9858073A1 *

Also Published As

Publication number Publication date
ZA985217B (en) 1999-01-07
JP3421355B2 (ja) 2003-06-30
AR015892A1 (es) 2001-05-30
AU8058398A (en) 1999-01-04
MY133532A (en) 2007-11-30
CA2293708A1 (fr) 1998-12-23
CA2293708C (fr) 2004-05-11
WO1998058073A1 (fr) 1998-12-23
IN187248B (fr) 2002-03-09
JP2000512862A (ja) 2000-10-03

Similar Documents

Publication Publication Date Title
US7126003B2 (en) Method for producing 2-azetidinone derivative
US6261830B1 (en) Enzymatic process for stereoselective preparation of a tertiary acid
WO1998058073A1 (fr) Resolution cinetique enzymatique d'un intermediaire utilise pour la preparation de composes tricycliques substitues
US5286650A (en) Process for the production of optically-active 4-amino-3-hydroxycarboxylic acids
US6037166A (en) Enzymatic kinetic resolution of an intermediate useful for preparing substituted tricyclics
US6063615A (en) Enzymatic acylation of amino acid esters using a carboxylic acid ester substituted with oxygen on the alpha carbon
WO2004003001A1 (fr) Procede de resolution enzymatique de 1,3-dioxolane-4-carboxylates
JP2703768B2 (ja) 光学活性３−ヒドロキシピロリジン誘導体の製造法
EP0512848B1 (fr) Résolution enzymatique d'esters d'acides alpha-tertiaire carboxyliques
US4865771A (en) Process for preparing L(-)-carnitine chloride from 3,4-epoxybutyric esters and novel intermediate compounds
US20040053401A1 (en) Preparation of enantiomerically pure hydroxy esters and acids
MXPA99011912A (en) Enzymatic kinetic resolution of an intermediate useful for preparing substituted tricyclics
US6524844B2 (en) Process for preparing optically active 1-amino-4-(hydroxymethyl) cyclopent-2-ene derivatives
EP1283200A2 (fr) Présurseurs de la paroxétine optiquement purs
KR100758512B1 (ko) 효소적 방법에 의한 광학활성3-히드록시-3-페닐프로피온산과 광학활성3-아실옥시-3-페닐프로피온산의 제조 방법
EP1428888B1 (fr) Procédé de préparation d'esters de (1S,4R)-(-)-4-Hydroxycyclopentényle
JP2007117034A (ja) 光学活性ニペコチン酸化合物の製造方法
JPWO2009099140A1 (ja) 光学活性インドリン−２−カルボン酸類またはその誘導体の製造方法
EP2071033A1 (fr) Procédé de production d'un composé de succinimide optiquement actif
US7439036B2 (en) Process for producing optically active octahydro-1H-indole-2-carboxylic acid
KR20040042666A (ko) 효소적 방법에 의한 광학활성 (ｒ)-2-아미노-1-부탄올의제조방법
JP2009263341A (ja) 光学活性ニペコチン酸エステル誘導体の製造法
EP2264039A1 (fr) Procédé de préparation du fosinopril et ses intermédiaires
Martin Hydrolase-Mediated Resolutions with Carbonic Acid Derivatives
JPH05111392A (ja) 光学活性含硫黄化合物の製造法

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19991129

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LI LU NL PT SE

AX Request for extension of the european patent

Free format text: LT PAYMENT 19991129;LV PAYMENT 19991129;RO PAYMENT 19991129

17Q First examination report despatched

Effective date: 20031124

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20040831